Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy

Gene Therapy

Volumn 12, Issue 2, 2005, Pages 187-193

  Breidenbach, M ^a,d   Rein, D T ^a   Everts, M ^a   Glasgow, J N ^b   Wang, M ^a   Passineau, M J ^a   Alvarez, R D ^c   Korokhov, N ^b   Curiel, D T ^a  

^a Gene Therapy Center   (United States)

^b VectorLogics Inc   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Adenovirus; Dual targeting; Tissue specific promoters; Transcriptional targeting; Transductional targeting

Indexed keywords

ADENOVIRUS VECTOR; LUCIFERASE; MEMBRANE PROTEIN; MESOTHELIN MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VIVO STUDY; MESOTHELIUM CELL; MOUSE; MOUSE STRAIN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 13244298253     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302404     Document Type: Article

References (21)

1. Jemal A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Hallenbeck PL et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
3. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-140.
4. Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer 1994; 57: 90-97.
5. Urwin D, Lake RA. Structure of the mesothelin/MPF gene and characterization of its promoter. Mol Cell Biol Res Commun 2000; 3: 26-32.
6. Hassan R et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002; 8: 3520-3526.
7. Frierson Jr HF et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003; 34: 605-609.
8. Barker SD et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57-63.
9. Schaner ME et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14: 4376-4386.
10. Casado E et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-2504.
11. Hemminki A et al. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001; 61: 6377-6381.
12. Fan D et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 2002; 1: 595-600.
13. Brinkmann U et al. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int J Cancer 1997; 71: 638-644.
14. Reynolds PN et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838-842.
15. Vile RG, Sunassee K, Diaz RM. Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today 1998; 4: 84-92.
16. Barker SD et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy 2003; 10: 1198-1204.
17. Barnett BG, Tillman BW, Curiel DT, Douglas JT. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther 2002; 6: 377-385.
18. Lam JT et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003; 10: 377-387.
19. Kanerva A et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
20. Danilov SM et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1335-L1347.
21. Korokhov N et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003; 77: 12931-12940.